0 01/04/2024 31/03/2025 2025-03-31 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2024-04-01 Sage Accounts Production 24.0 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 08528042 2024-04-01 2025-03-31 08528042 2025-03-31 08528042 2024-03-31 08528042 2023-04-01 2024-03-31 08528042 2024-03-31 08528042 2023-03-31 08528042 core:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 08528042 bus:Director2 2024-04-01 2025-03-31 08528042 core:WithinOneYear 2025-03-31 08528042 core:WithinOneYear 2024-03-31 08528042 core:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 08528042 core:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 08528042 core:ShareCapital 2025-03-31 08528042 core:ShareCapital 2024-03-31 08528042 core:SharePremium 2025-03-31 08528042 core:SharePremium 2024-03-31 08528042 core:RetainedEarningsAccumulatedLosses 2025-03-31 08528042 core:RetainedEarningsAccumulatedLosses 2024-03-31 08528042 core:ShareCapital 2023-03-31 08528042 core:SharePremium 2023-03-31 08528042 core:RetainedEarningsAccumulatedLosses 2023-03-31 08528042 core:PreviouslyStatedAmount core:ShareCapital 2025-03-31 08528042 bus:SmallEntities 2024-04-01 2025-03-31 08528042 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 08528042 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 08528042 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 08528042 bus:FullAccounts 2024-04-01 2025-03-31
Company registration number: 08528042
Eurekagen Limited
Unaudited filleted financial statements
31 March 2025
Eurekagen Limited
Contents
Statement of financial position
Statement of changes in equity
Notes to the financial statements
Eurekagen Limited
Statement of financial position
31 March 2025
2025 2024
Note £ £ £ £
Fixed assets
Intangible assets 4 26,696 24,613
_________ _________
26,696 24,613
Current assets
Debtors 5 3,000 2,441
Cash at bank and in hand 2 4
_________ _________
3,002 2,445
Creditors: amounts falling due
within one year 6 ( 60,251) ( 50,949)
_________ _________
Net current liabilities ( 57,249) ( 48,504)
_________ _________
Total assets less current liabilities ( 30,553) ( 23,891)
_________ _________
Net liabilities ( 30,553) ( 23,891)
_________ _________
Capital and reserves
Called up share capital 1,000 1,000
Share premium account 149,500 149,500
Profit and loss account ( 181,053) ( 174,391)
_________ _________
Shareholders deficit ( 30,553) ( 23,891)
_________ _________
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 28 November 2025 , and are signed on behalf of the board by:
Mr Graham Edwards
Director
Company registration number: 08528042
Eurekagen Limited
Statement of changes in equity
Year ended 31 March 2025
Called up share capital Share premium account Profit and loss account Total
£ £ £ £
At 1 April 2023 1,000 149,500 ( 162,585) ( 12,085)
Loss for the year ( 11,806) ( 11,806)
_______ _________ _________ _________
Total comprehensive income for the year - - ( 11,806) ( 11,806)
_______ _________ _________ _________
At 31 March 2024 and 1 April 2024 1,000 149,500 ( 174,391) ( 23,891)
Loss for the year ( 6,662) ( 6,662)
_______ _________ _________ _________
Total comprehensive income for the year - - ( 6,662) ( 6,662)
_______ _________ _________ _________
At 31 March 2025 1,000 149,500 ( 181,053) ( 30,553)
_______ _________ _________ _________
Eurekagen Limited
Notes to the financial statements
Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England & Wales. The address of the registered office is Ort House, 147 Arlington Road, London NW1 7ET.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard appplicable in the UK and Republic of Ireland'.The preparation of financial statements in compliance with FRS 102 Section 1A requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company's accounting policies.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The financial statements have been prepared on the basis that the Company continues to be a going concern. The directors have indicated that they will continue to support the company for a period of at least 12 months from the date of signing these financial statements.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at a revalued amount, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
Combined other intangible assets - 20 % straight line
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Research and development
Research expenditure is written off in the year in which it is incurred. Development expenditure incurred is capitalised as an intangible asset only when all of the following criteria are met: - It is technically feasible to complete the intangible asset so that it will be available for use or sale; - There is the intention to complete the intangible asset and use or sell it; - There is the ability to use or sell the intangible asset; - The use or sale of the intangible asset will generate probable future economic benefits; - There are adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and - The expenditure attributable to the intangible asset during its development can be measured reliably. Expenditure that does not meet the above criteria is expensed as incurred.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Debt instruments are subsequently measured at amortised cost.
4. Intangible assets
Development costs
£
Cost
At 1 April 2024 63,656
Additions 2,083
_________
At 31 March 2025 65,739
_________
Amortisation
At 1 April 2024 and 31 March 2025 39,043
_________
Carrying amount
At 31 March 2025 26,696
_________
At 31 March 2024 24,613
_________
5. Debtors
2025 2024
£ £
VAT recoverable 3,000 2,441
_________ _________
6. Creditors: amounts falling due within one year
2025 2024
£ £
Trade creditors 2,462 4,320
Accruals and deferred income 9,730 4,000
Director loan accounts 38 38
Other creditors 48,021 42,591
_________ _________
60,251 50,949
_________ _________